GlaxoSmithKline agrees to $105 million settlement

Published



SAN DIEGO (AP) — GlaxoSmithKline PLC will pay $105 million to dozens of states to settle allegations that it unlawfully marketed its asthma drug Advair and the antidepressants Paxil and Wellbutrin.

Under the settlement announced Wednesday, the London-based pharmaceutical also agreed to rules that bar it from paying doctors to promote its products; providing financial incentives that encourage salespeople to market drugs for unapproved uses; marketing drugs using results from inadequate studies or making unapproved claims that a product was “better, more effective, safer or has less serious side effects,” according to a statement from California Attorney General Kamala D. Harris.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.